Amneal launches FDA-approved 120 mg generic lanreotide
Amneal Pharmaceuticals says it received FDA approval for a 120 mg generic lanreotide (Somatuline Depot) and has launched the injectable with in-house manufacturing and a CGT designation.
Amneal Pharmaceuticals says it received FDA approval for a 120 mg generic lanreotide (Somatuline Depot) and has launched the injectable with in-house manufacturing and a CGT designation.